Transgene and BioInvent Receive Approval From ANSM to Proceed With Phase I/IIa Trial of Anti-CTLA4-armed Oncolytic Virus BT-001 in Solid Tumors
The Pharma Data
JANUARY 18, 2021
The first patient is expected to be enrolled in this trial in the upcoming weeks. BT-001 is being co-developed through a 50/50 collaboration between Transgene and BioInvent. IN FRANCE, FOUR CLINICAL CENTERS WILL ENROLL PATIENTS. “ The trial has been approved in Europe (France and Belgium) and will be next conducted in the USA.
40 
Let's personalize your content